Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 8.758
Filter
1.
Int J Biol Sci ; 20(9): 3317-3333, 2024.
Article in English | MEDLINE | ID: mdl-38993555

ABSTRACT

The glomerular podocyte, a terminally differentiated cell, is crucial for the integrity of the glomerular filtration barrier. The re-entry of podocytes into the mitotic phase results in injuries or death, known as mitotic catastrophe (MC), which significantly contributes to the progression of diabetic nephropathy (DN). Furthermore, P62-mediated autophagic flux has been shown to regulate DN-induced podocyte injury. Although previous studies, including ours, have demonstrated that ursolic acid (UA) mitigates podocyte injury by enhancing autophagy under high glucose conditions, the protective functions and potential regulatory mechanisms of UA against DN have not been fully elucidated. For aiming to investigate the regulatory mechanism of podocyte injuries in DN progression, and the protective function of UA treatment against DN progression, we utilized db/db mice and high glucose (HG)-induced podocyte models in vivo and in vitro, with or without UA administration. Our findings indicate that UA treatment reduced DN progression by improving biochemical indices. P62 accumulation led to Murine Double Minute gene 2 (MDM2)-regulated MC in podocytes during DN, which was ameliorated by UA through enhanced P62-mediated autophagy. Additionally, the overexpression of NF-κB p65 or TNF-α abolished the protective effects of UA both in vivo and in vitro. Overall, our results provide strong evidence that UA could be a potential therapeutic agent for DN, regulated by inhibiting podocyte MC through the NF-κB/MDM2/Notch1 pathway by targeting autophagic-P62 accumulation.


Subject(s)
Autophagy , Diabetic Nephropathies , Podocytes , Triterpenes , Ursolic Acid , Podocytes/drug effects , Podocytes/metabolism , Animals , Triterpenes/pharmacology , Triterpenes/therapeutic use , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/drug therapy , Mice , Autophagy/drug effects , Mitosis/drug effects , Male , Mice, Inbred C57BL
2.
Mar Drugs ; 22(7)2024 Jun 26.
Article in English | MEDLINE | ID: mdl-39057402

ABSTRACT

Eight sulfated triterpene glycosides, peronioside A (1) and psolusosides A (2), B (3), G (4), I (5), L (6), N (7) and P (8), were isolated from the sea cucumber Psolus peronii. Peronioside A (1) is a new glycoside, while compounds 2-8 were found previously in Psolus fabricii, indicating the phylogenetic and systematic closeness of these species of sea cucumbers. The activity of 1-8 against human erythrocytes and their cytotoxicity against the breast cancer cell lines MCF-7, T-47D and triple-negative MDA-MB-231 were tested. The most active against cancer cell compounds, psolusosides A (2) and L (6), which were not cytotoxic to the non-transformed cells of the mammary gland, were chosen to study the inhibition of the migration, formation and growth of colonies of the cancer cell lines. Glycoside 2 effectively inhibited the growth of colonies and the migration of the MDA-MB-231 cell line. Compound 6 blocked the growth of colonies of T-47D cells and showed a pronounced antimigration effect on MDA-MB-231 cells. The quantitative structure-activity relationships (QSAR) indicated the strong impact on the activity of the form and size of the molecules, which is connected to the length and architecture of the carbohydrate chain, the distribution of charge on the molecules' surface and various aspects of hydrogen bond formation, depending on the quantity and positions of the sulfate groups. The QSAR calculations were in good accordance with the observed SAR tendencies.


Subject(s)
Antineoplastic Agents , Breast Neoplasms , Glycosides , Quantitative Structure-Activity Relationship , Sea Cucumbers , Triterpenes , Humans , Glycosides/pharmacology , Glycosides/chemistry , Glycosides/isolation & purification , Animals , Triterpenes/pharmacology , Triterpenes/chemistry , Triterpenes/isolation & purification , Sea Cucumbers/chemistry , Antineoplastic Agents/pharmacology , Antineoplastic Agents/chemistry , Cell Line, Tumor , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Female , MCF-7 Cells , Cell Movement/drug effects , Erythrocytes/drug effects
3.
BMC Infect Dis ; 24(1): 688, 2024 Jul 10.
Article in English | MEDLINE | ID: mdl-38987682

ABSTRACT

BACKGROUND: Dengue fever has become a significant worldwide health concern, because of its high morbidity rate and the potential for an increase in mortality rates due to lack of adequate treatment. There is an immediate need for the development of effective medication for dengue fever. METHODS: Homology modeling of dengue virus (DENV) non-structural 4B (NS4B) protein was performed by SWISS-MODEL to predict the 3D structure of the protein. Structure validation was conducted using PROSA, PROCHECK, Ramachandran plot, and VERIFY-3D. MOE software was used to find out the in-Silico inhibitory potential of the five triterpenoids against the DENV-NS4B protein. RESULTS: The SWISS-MODEL was employed to predict the three-dimensional protein structure of the NS4B protein. Through molecular docking, it was found that the chosen triterpenoid NS4B protein had a high binding affinity interaction. It was observed that the NS4B protein binding energy for 15-oxoursolic acid, betulinic acid, ursolic acid, lupeol, and 3-o-acetylursolic acid were - 7.18, - 7.02, - 5.71, - 6.67 and - 8.00 kcal/mol, respectively. CONCLUSIONS: NS4B protein could be a promising target which showed good interaction with tested triterpenoids which can be developed as a potential antiviral drug for controlling dengue virus pathogenesis by inhibiting viral replication. However, further investigations are necessary to validate and confirm their efficacy.


Subject(s)
Antiviral Agents , Dengue Virus , Molecular Docking Simulation , Triterpenes , Viral Nonstructural Proteins , Viral Nonstructural Proteins/chemistry , Viral Nonstructural Proteins/metabolism , Triterpenes/pharmacology , Triterpenes/chemistry , Dengue Virus/drug effects , Dengue Virus/chemistry , Antiviral Agents/pharmacology , Antiviral Agents/chemistry , Protein Binding , Humans , Dengue/virology , Dengue/drug therapy , Protein Conformation , Membrane Proteins
4.
Eur J Pharmacol ; 978: 176805, 2024 Sep 05.
Article in English | MEDLINE | ID: mdl-38950838

ABSTRACT

Cucurbitacin B (CuB) is a compound found in plants like Cucurbitaceae that has shown promise in fighting cancer, particularly in lung cancer. However, the specific impact of CuB on ferroptosis and how it works in lung cancer cells has not been fully understood. Our research has discovered that CuB can effectively slow down the growth of non-small cell lung cancer (NSCLC) cells. Even in small amounts, it was able to inhibit the growth of various NSCLC cell lines. This inhibitory effect was reversed when ferroptosis inhibitors DFO, Lip-1 and Fer-1 were introduced. CuB was found to increase the levels of reactive oxygen species (ROS), lipid ROS, MDA, and ferrous ions within H358 lung cancer cells, leading to a decrease in GSH, mitochondrial membrane potential (MMP) and changes in ferroptosis-related proteins in a dose-dependent manner. These findings were also confirmed in A549 lung cancer cells. In A549 cells, different concentrations of CuB induced the accumulation of intracellular lipid ROS, ferrous ions and changes in ferroptosis-related indicators in a concentration-dependent manner. Meanwhile, the cytotoxic effect induced by CuB in A549 cells was counteracted by ferroptosis inhibitors DFO and Fer-1. Through network pharmacology, we identified potential targets related to ferroptosis in NSCLC cells treated with CuB, with STAT3 targets showing high scores. Further experiments using molecular docking and cell thermal shift assay (CETSA) revealed that CuB interacts with the STAT3 protein. Western blot and immunofluorescence staining demonstrated that CuB inhibits the phosphorylation of STAT3 (P-STAT3) in H358 cells. Silencing STAT3 enhanced CuB-induced accumulation of lipid ROS and iron ions, as well as the expression of ferroptosis-related proteins. On the other hand, overexpression of STAT3 reversed the effects of CuB-induced ferroptosis. The results indicate that CuB has the capability to suppress STAT3 activation, resulting in ferroptosis, and could be a promising treatment choice for NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Ferroptosis , Lung Neoplasms , Reactive Oxygen Species , STAT3 Transcription Factor , Triterpenes , Humans , Ferroptosis/drug effects , STAT3 Transcription Factor/metabolism , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Lung Neoplasms/drug therapy , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Triterpenes/pharmacology , Reactive Oxygen Species/metabolism , A549 Cells , Cell Line, Tumor , Molecular Docking Simulation , Cell Proliferation/drug effects , Membrane Potential, Mitochondrial/drug effects
5.
J Nat Prod ; 87(7): 1763-1777, 2024 Jul 26.
Article in English | MEDLINE | ID: mdl-38970504

ABSTRACT

The isolation, structure determination, and biological evaluation of constituents from the organic extract of Turraea delphinensis Wahlert (Meliaceae) resulted in the isolation of 51 secondary metabolites, including 14 new terpenoids (six cycloartanes, four tirucallanes/euphanes, three limonoids, and a 7-keto sterol). Among the new compounds, 1 is the first triterpenoid with a trioxaspiro[4.4]nonane side chain, while 11-13 are the first 17-γ-lactone tetranortriterpenoids with four oxygenated functional groups at C-1, -3, -6, and -7. The isolated compounds were evaluated for antiproliferative activity against five human tumor cell lines, including a vinblastine-resistant cell line.


Subject(s)
Antineoplastic Agents, Phytogenic , Drug Screening Assays, Antitumor , Meliaceae , Terpenes , Triterpenes , Humans , Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/isolation & purification , Terpenes/pharmacology , Terpenes/chemistry , Terpenes/isolation & purification , Molecular Structure , Meliaceae/chemistry , Triterpenes/pharmacology , Triterpenes/chemistry , Triterpenes/isolation & purification , Cell Line, Tumor , Limonins/pharmacology , Limonins/chemistry , Limonins/isolation & purification , Cell Proliferation/drug effects
6.
Int J Mol Med ; 54(3)2024 Sep.
Article in English | MEDLINE | ID: mdl-38994762

ABSTRACT

Age­related macular degeneration (AMD) is an ocular disease that threatens the visual function of older adults worldwide. Key pathological processes involved in AMD include oxidative stress, inflammation and choroidal vascular dysfunction. Retinal pigment epithelial cells and Müller cells are most susceptible to oxidative stress. Traditional herbal medicines are increasingly being investigated in the field of personalized medicine in ophthalmology. Triptonide (Tn) is a diterpene tricyclic oxide, the main active ingredient in the extract from the Chinese herbal medicinal plant Tripterygium wilfordii, and is considered an effective immunosuppressant and anti­inflammatory drug. The present study investigated the potential beneficial role of Tn in retinal oxidative damage in order to achieve personalized treatment for early AMD. An oxidative stress model of retinal cells induced by H2O2 and a retinal injury model of mice induced by light and N­Methyl­D­aspartic acid were constructed. In vitro, JC­1 staining, flow cytometry and apoptosis assay confirmed that low concentrations of Tn effectively protected retinal cells from oxidative damage, and reverse transcription­quantitative PCR and western blotting analyses revealed that Tn reduced the expression of retinal oxidative stress­related genes and inflammatory factors, which may depend on the PI3K/AKT/mTOR­induced Nrf2 signaling pathway. In vivo, by retinal immunohistochemistry, hematoxylin and eosin staining and electroretinogram assay, it was found that retinal function and structure improved and choroidal neovascularization was significantly inhibited after Tn pretreatment. These results suggested that Tn is an efficient Nrf2 activator, which can be expected to become a new intervention for diseases such as AMD, to inhibit retinal oxidative stress damage and pathological neovascularization.


Subject(s)
NF-E2-Related Factor 2 , Oxidative Stress , Retina , Signal Transduction , Oxidative Stress/drug effects , Animals , NF-E2-Related Factor 2/metabolism , Signal Transduction/drug effects , Mice , Retina/drug effects , Retina/metabolism , Retina/pathology , Triterpenes/pharmacology , Male , Apoptosis/drug effects , Humans , Mice, Inbred C57BL , Protective Agents/pharmacology , Cell Line , Hydrogen Peroxide
7.
J Cell Mol Med ; 28(14): e18375, 2024 Jul.
Article in English | MEDLINE | ID: mdl-39039796

ABSTRACT

Celastrol, a bioactive molecule extracted from the plant Tripterygium wilfordii Hook F., possesses anti-inflammatory, anti-obesity and anti-tumour properties. Despite its efficacy in improving erythema and scaling in psoriatic mice, the specific therapeutic mechanism of celastrol in atopic dermatitis (AD) remains unknown. This study aims to examine the role and mechanism of celastrol in AD using TNF-α-stimulated HaCaT cells and DNCB-induced Balb/c mice as in vitro and in vivo AD models, respectively. Celastrol was found to inhibit the increased epidermal thickness, reduce spleen and lymph node weights, attenuate inflammatory cell infiltration and mast cell degranulation and decrease thymic stromal lymphopoietin (TSLP) as well as various inflammatory factors (IL-4, IL-13, TNF-α, IL-5, IL-31, IL-33, IgE, TSLP, IL-17, IL-23, IL-1ß, CCL11 and CCL17) in AD mice. Additionally, celastrol inhibited Ezrin phosphorylation at Thr567, restored mitochondrial network structure, promoted translocation of Drp1 to the cytoplasm and reduced TNF-α-induced cellular reactive oxygen species (ROS), mitochondrial ROS (mtROS) and mitochondrial membrane potential (MMP) production. Interestingly, Mdivi-1 (a mitochondrial fission inhibitor) and Ezrin-specific siRNAs lowered inflammatory factor levels and restored mitochondrial reticular formation, as well as ROS, mtROS and MMP production. Co-immunoprecipitation revealed that Ezrin interacted with Drp1. Knocking down Ezrin reduced mitochondrial fission protein Drp1 phosphorylation and Fis1 expression while increasing the expression of fusion proteins Mfn1 and Mfn2. The regulation of mitochondrial fission and fusion by Ezrin was confirmed. Overall, celastrol may alleviate AD by regulating Ezrin-mediated mitochondrial fission and fusion, which may become a novel therapeutic reagent for alleviating AD.


Subject(s)
Cytokines , Cytoskeletal Proteins , Dermatitis, Atopic , Mice, Inbred BALB C , Mitochondrial Dynamics , Pentacyclic Triterpenes , Triterpenes , Animals , Mitochondrial Dynamics/drug effects , Pentacyclic Triterpenes/pharmacology , Dermatitis, Atopic/drug therapy , Dermatitis, Atopic/pathology , Dermatitis, Atopic/metabolism , Humans , Triterpenes/pharmacology , Mice , Cytokines/metabolism , Cytoskeletal Proteins/metabolism , Cytoskeletal Proteins/genetics , Thymic Stromal Lymphopoietin , Disease Models, Animal , Mitochondria/metabolism , Mitochondria/drug effects , Reactive Oxygen Species/metabolism , Tumor Necrosis Factor-alpha/metabolism , HaCaT Cells , Phosphorylation/drug effects
8.
Zhongguo Zhong Yao Za Zhi ; 49(13): 3619-3626, 2024 Jul.
Article in Chinese | MEDLINE | ID: mdl-39041134

ABSTRACT

The intervention effect of astragaloside Ⅳ(AS-Ⅳ) on atherosclerosis in apolipoprotein E gene knockout(ApoE)~(-/-) mice was observed based on the nuclear factor erythroid-2-related factor 2(Nrf2)/heme oxygenase-1(HO-1)/glutathione peroxidase 4(GPX4) signaling pathway to explore the potential mechanism of AS-Ⅳ in improving ferroptosis in atherosclerotic mice. This study established an atherosclerosis mouse model by feeding them a high-fat diet. After modeling for 8 weeks, ApoE~(-/-) mice were randomly divided into the model group, AS-Ⅳ group, AS-Ⅳ+Nrf2 inhibitor(ML385) group, and ferrostatin-1(Fer-1) group. Additionally, a blank control group was also established. Corresponding drugs were administered via intraperitoneal injection, with the control group receiving an equivalent amount of normal saline injection as the model group. After the experiment, serum biochemical levels were measured using an automatic blood lipid analyzer, hematoxylin-eosin(HE) staining was used to observe morphological changes in aortic sinus tissues, colorimetric methods were used to detect levels of ferrous ion(Fe~(2+)), malondialdehyde(MDA), glutathione(GSH), and superoxide dismutase(SOD) in mouse serum, immunofluorescence was used to observe the expressions of ferritin heavy chain 1(FTH1) and ferritin light chain(FTL) proteins in the aortic sinus of mice, Western blot was used to detect the protein levels of Nrf2, HO-1, and GPX4 in mouse aortic tissues, and transmission electron microscopy was used to observe ultrastructural changes in aortic tissues. RESULTS:: showed that compared to the control group, the model group of mice had significantly increased calcification and plaque deposition areas in the aortic sinus, increased mitochondrial membrane density, decreased or disappeared mitochondrial cristae, elevated levels of total cholesterol(TC), triglycerides(TG), low-density lipoprotein cholesterol(LDL-C), Fe~(2+), and MDA, decreased levels of high-density lipoprotein cholesterol(HDL-C), SOD, and GSH, and significant inhibition of Nrf2, HO-1, GPX4 proteins, as well as iron storage proteins FTH1 and FTL expressions in the aorta. Compared to the model group, AS-Ⅳ treatment resulted in decreased serum TC, TG, LDL-C, Fe~(2+), and MDA levels, increased HDL-C, SOD, and GSH levels, increased expressions of Nrf2, HO-1, and GPX4 proteins, and iron storage proteins FTH1 and FTL, and significant improvement in aortic tissue morphology. Compared to the AS-Ⅳ group, the Nrf2 inhibitor ML385 could reverse the therapeutic effect of AS-Ⅳ on atherosclerosis mice. These findings suggest that AS-Ⅳ can inhibit ferroptosis and improve atherosclerosis in ApoE~(-/-) mice, and its mechanism of action may be related to the regulation of the Nrf2/HO-1/GPX4 signaling pathway.


Subject(s)
Apolipoproteins E , Atherosclerosis , Ferroptosis , Heme Oxygenase-1 , NF-E2-Related Factor 2 , Phospholipid Hydroperoxide Glutathione Peroxidase , Saponins , Triterpenes , Animals , NF-E2-Related Factor 2/metabolism , NF-E2-Related Factor 2/genetics , Atherosclerosis/drug therapy , Atherosclerosis/metabolism , Atherosclerosis/genetics , Mice , Ferroptosis/drug effects , Saponins/pharmacology , Triterpenes/pharmacology , Apolipoproteins E/genetics , Male , Phospholipid Hydroperoxide Glutathione Peroxidase/metabolism , Phospholipid Hydroperoxide Glutathione Peroxidase/genetics , Heme Oxygenase-1/metabolism , Heme Oxygenase-1/genetics , Signal Transduction/drug effects , Mice, Knockout , Humans , Mice, Inbred C57BL
9.
Sci Adv ; 10(28): eadn0960, 2024 Jul 12.
Article in English | MEDLINE | ID: mdl-38996025

ABSTRACT

Celastrol (CEL), an active compound isolated from the root of Tripterygium wilfordii, exhibits broad anticancer activities. However, its poor stability, narrow therapeutic window and numerous adverse effects limit its applications in vivo. In this study, an adenosine triphosphate (ATP) activatable CEL-Fe(III) chelate was designed, synthesized, and then encapsulated with a reactive oxygen species (ROS)-responsive polymer to obtain CEL-Fe nanoparticles (CEL-Fe NPs). In normal tissues, CEL-Fe NPs maintain structural stability and exhibit reduced systemic toxicity, while at the tumor site, an ATP-ROS-rich tumor microenvironment, drug release is triggered by ROS, and antitumor potency is restored by competitive binding of ATP. This intelligent CEL delivery system improves the biosafety and bioavailability of CEL for cancer therapy. Such a CEL-metal chelate strategy not only mitigates the challenges associated with CEL but also opens avenues for the generation of CEL derivatives, thereby expanding the therapeutic potential of CEL in clinical settings.


Subject(s)
Adenosine Triphosphate , Pentacyclic Triterpenes , Prodrugs , Reactive Oxygen Species , Pentacyclic Triterpenes/pharmacology , Pentacyclic Triterpenes/chemistry , Prodrugs/chemistry , Prodrugs/pharmacology , Adenosine Triphosphate/metabolism , Humans , Animals , Reactive Oxygen Species/metabolism , Mice , Cell Line, Tumor , Triterpenes/chemistry , Triterpenes/pharmacology , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Chelating Agents/chemistry , Chelating Agents/pharmacology , Neoplasms/drug therapy , Neoplasms/metabolism , Neoplasms/pathology , Tumor Microenvironment/drug effects , Drug Liberation , Nanoparticles/chemistry , Xenograft Model Antitumor Assays , Ferric Compounds/chemistry
10.
Expert Opin Ther Pat ; 34(8): 723-732, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38965930

ABSTRACT

INTRODUCTION: Boswellic acids (BAs) are a group of pentacyclic triterpenoids of the ursane and oleanane type. They have shown very interesting biological properties that have led to the development of a number of synthesis protocols. Both natural BAs and their synthetic derivatives may be useful in the treatment of a variety of cancers, viral infections and inflammatory diseases. AREAS COVERED: This review covers patents relating to the therapeutic activities of natural BAs and their synthetic derivatives. The latest patented studies of boswellic acids (are summarized by using the keywords 'boswellic acid,' in SciFinder, PubMed, and Google Patents and databases in the year from 2016 to 2023. EXPERT OPINION: Boswellic acids have shown potent antiviral, anticancer and anti-inflammatory potential. Few BAs analogues have been prepared by modification at the C24-CO2H functional groups. In particular, the C-24 amide and amino analogues have shown enhanced anticancer effects compared to the parent AKBA. In addition, BAs have the ability to form conjugates with other antiviral, anti-inflammatory and anticancer drugs that synergistically enhance their biological efficacy. In addition, this conjugation strategy will increase the solubility and bioavailability of BAs, which is one of the most important issues in the development of BAs.


Subject(s)
Anti-Inflammatory Agents , Antiviral Agents , Drug Development , Neoplasms , Patents as Topic , Triterpenes , Humans , Triterpenes/pharmacology , Triterpenes/chemistry , Animals , Antiviral Agents/pharmacology , Anti-Inflammatory Agents/pharmacology , Neoplasms/drug therapy , Antineoplastic Agents/pharmacology , Inflammation/drug therapy , Virus Diseases/drug therapy , Biological Availability
11.
Funct Integr Genomics ; 24(4): 126, 2024 Jul 16.
Article in English | MEDLINE | ID: mdl-39012393

ABSTRACT

Colorectal cancer (CRC) is a prevalent malignancy affecting the human digestive tract. Triptonide has been shown to have some anticancer activity, but its effect in CRC is vague. Herein, we examined the effect of triptonide on CRC. In this study, the results of bioinformatics analysis displayed that triptonide may regulate ferroptosis in CRC by modulating GPX4 and SLC7A11. In HCT116 and LoVo cells, the expression levels of GPX4 and SLC7A11 were significantly reduced after triptonide management versus the control group. Triptonide inhibited proliferation, but promoted ferroptosis in CRC cells. SLC7A11 upregulation overturned the effects of triptonide on proliferation and ferroptosis in CRC cells. Triptonide inhibited activation of the PI3K/AKT/Nrf2 signaling in CRC cells. Activation of the PI3K/AKT signaling or Nrf2 upregulation overturned the effects of triptonide on proliferation and ferroptosis in CRC cells. Triptonide suppressed CRC cell growth in vivo by modulating SLC7A11 and GPX4. In conclusion, Triptonide repressed proliferation and facilitated ferroptosis of CRC cells by repressing the SLC7A11/GPX4 axis through inactivation of the PI3K/AKT/Nrf2 signaling.


Subject(s)
Amino Acid Transport System y+ , Cell Proliferation , Colorectal Neoplasms , Ferroptosis , Phospholipid Hydroperoxide Glutathione Peroxidase , Signal Transduction , Ferroptosis/drug effects , Humans , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Phospholipid Hydroperoxide Glutathione Peroxidase/metabolism , Phospholipid Hydroperoxide Glutathione Peroxidase/genetics , Animals , Mice , Cell Proliferation/drug effects , Amino Acid Transport System y+/metabolism , Amino Acid Transport System y+/genetics , Signal Transduction/drug effects , Triterpenes/pharmacology , NF-E2-Related Factor 2/metabolism , NF-E2-Related Factor 2/genetics , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-akt/genetics , Phosphatidylinositol 3-Kinases/metabolism , Phosphatidylinositol 3-Kinases/genetics , Cell Line, Tumor , HCT116 Cells , Mice, Nude , Gene Expression Regulation, Neoplastic/drug effects
12.
PLoS One ; 19(7): e0305058, 2024.
Article in English | MEDLINE | ID: mdl-38954702

ABSTRACT

OBJECTIVES: Astragaloside IV (AS-IV) is a natural triterpenoid saponin compound with a variety of pharmacological effects, and several studies have clarified its anti-inflammatory effects, which may make it an effective alternative treatment against inflammation. In the study, we aimed to investigate whether AS-IV could attenuate the inflammatory response to acute lung injury and its mechanisms. METHODS: Different doses of AS-IV (20mg·kg-1, 40mg·kg-1, and 80mg·kg-1) were administered to the ALI rat model, followed by collection of serum and broncho alveolar lavage fluid (BALF) for examination of the inflammatory response, and HE staining of the lung and colon tissues, and interpretation of the potential molecular mechanisms by quantitative real-time PCR (qRT-PCR), Western blotting (WB). In addition, fecal samples from ALI rats were collected and analyzed by 16S rRNA sequencing. RESULTS: AS-IV decreased the levels of TNF-α, IL-6, and IL-1ß in serum and BALF of mice with Acute lung injury (ALI). Lung and colon histopathology confirmed that AS-IV alleviated inflammatory infiltration, tissue edema, and structural changes. qRT-PCR and WB showed that AS-IV mainly improved inflammation by inhibiting the expression of PI3K, AKT and mTOR mRNA, and improved the disorder of intestinal microflora by increasing the number of beneficial bacteria and reducing the number of harmful bacteria. CONCLUSION: AS-IV reduces the expression of inflammatory factors by inhibiting the PI3K/AKT/mTOR pathway and optimizes the composition of the gut microflora in AIL rats.


Subject(s)
Acute Lung Injury , Gastrointestinal Microbiome , Phosphatidylinositol 3-Kinases , Proto-Oncogene Proteins c-akt , Saponins , Signal Transduction , TOR Serine-Threonine Kinases , Triterpenes , Animals , Saponins/pharmacology , Saponins/therapeutic use , Triterpenes/pharmacology , Acute Lung Injury/drug therapy , Acute Lung Injury/microbiology , Acute Lung Injury/pathology , Acute Lung Injury/metabolism , TOR Serine-Threonine Kinases/metabolism , Gastrointestinal Microbiome/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Signal Transduction/drug effects , Rats , Male , Mice , Rats, Sprague-Dawley , Inflammation/drug therapy , Bronchoalveolar Lavage Fluid/chemistry , Lung/pathology , Lung/drug effects , Lung/microbiology , Lung/metabolism , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use
13.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi ; 40(6): 501-507, 2024 Jun.
Article in Chinese | MEDLINE | ID: mdl-38952089

ABSTRACT

Objective To investigate the effects of astragaloside IV(AS-IV) on the balance of T helper type 1 (Th1) and Th2 cells in mice with IgA nephropathy (IgAN) and its possible mechanism. Methods The IgAN model of BALB/c mice was established. Successfully modeled mice were randomly divided into four groups: model, AS-IV low dose, AS-IV medium dose and AS-IV high dose groups, with 10 mice in each group. Another 10 mice served as the control group. Mice in the low, medium and high dose groups were administered 12.5, 25 and 50 mg/kg AS-IV suspension (prepared in normal saline) by gavage, while the control and model groups were given an equivalent volume of normal saline. The 24-hour urinary protein (24 h UPr) content and urine red blood cell count were measured in each group. The levels of blood urea nitrogen (BUN), serum creatinine (Scr) and albumin (ALB) were determined. Serum interferon γ (IFN-γ), interleukin 4 (IL-4) and IL-10 levels were detected by ELISA. The ratio of Th1/Th2 cells in peripheral blood of mice was detected using flow cytometry. Histopathological changes in the kidney of mice were observed by HE staining. RT-PCR and Western blot were used to detect the mRNA and protein expressions of T cell immunoglobulin and mucin domain gene 1 (TIM-1), Toll-like receptor 4 (TLR4) in mouse kidney tissue. Results Compared with the model group, in weeks 12 and 15, the urine red blood cell count, 24 h UPr, BUN, Scr, levels of IL-4 and IL-10, the proportion of Th2 cells, as well as the mRNA and protein expression levels of TIM-1 and TLR4 were significantly decreased in the low, medium and high dose groups of AS-IV, and the levels of ALB, IFN-γ, the proportion of Th1 cells and Th1/Th2 cell ratio were increased, with the high-dose group showing the best effects. Conclusion AS-IV can inhibit TIM-1 signaling pathway, increase the Th1/Th2 cell ratio, inhibit the inflammatory reaction, and alleviate the renal injury in IgAN mice.


Subject(s)
Glomerulonephritis, IGA , Hepatitis A Virus Cellular Receptor 1 , Mice, Inbred BALB C , Saponins , Signal Transduction , Th1 Cells , Th2 Cells , Triterpenes , Animals , Hepatitis A Virus Cellular Receptor 1/metabolism , Hepatitis A Virus Cellular Receptor 1/genetics , Triterpenes/pharmacology , Glomerulonephritis, IGA/drug therapy , Glomerulonephritis, IGA/metabolism , Glomerulonephritis, IGA/immunology , Saponins/pharmacology , Th1 Cells/drug effects , Th1 Cells/immunology , Th1 Cells/metabolism , Signal Transduction/drug effects , Th2 Cells/drug effects , Th2 Cells/immunology , Th2 Cells/metabolism , Mice , Toll-Like Receptor 4/metabolism , Toll-Like Receptor 4/genetics , Interleukin-4/genetics , Interleukin-4/metabolism , Kidney/drug effects , Kidney/pathology , Kidney/metabolism , Interleukin-10/genetics , Interleukin-10/metabolism , Interferon-gamma/metabolism , Interferon-gamma/genetics , Male , Female
14.
PeerJ ; 12: e17691, 2024.
Article in English | MEDLINE | ID: mdl-38978752

ABSTRACT

Background: Oligospermia is one of the most common reasons for male infertility which is troubling numerous couples of child-bearing age. This investigation scrutinizes the implications and mechanistic underpinnings of ursolic acid's effect on busulfan-induced oligospermia in mouse models. Methods: A singular intraperitoneal injection of busulfan at a dosage of 30 mg/kg induced oligospermia. Two weeks subsequent to this induction, mice were subjected to various dosages of ursolic acid (10, 30, and 50 mg/kg body weight, respectively) on a daily basis for four consecutive weeks. Following this treatment period, a meticulous analysis of epididymal sperm parameters, encompassing concentration and motility, was conducted using a computer-assisted sperm analysis system. The histopathology of the mice testes was performed utilizing hematoxylin and eosin staining, and the cytoskeleton regeneration of the testicular tissues was analyzed via immunofluorescent staining. Serum hormone levels, including testosterone, luteinizing hormone, and follicle-stimulating hormone, as well as reactive oxygen species levels (inclusive of reactive oxygen species and malondialdehyde), were gauged employing specific enzyme-linked immunosorbent assay kits. Differentially expressed genes of testicular mRNA between the oligospermia-induced group and the various ursolic acid treatment groups were identified through RNA sequencing analysis. Results: The results revealed that a dosage of 50 mg/kg ursolic acid treatment could increase the concentration of epididymal sperm in oligospermia mice, promote the recovery of testicular morphology, regulate hormone levels and ameliorate oxidative damage. The mechanism research results indicated that ursolic acid increased the expression level of genes related to motor proteins in oligospermia mice.


Subject(s)
Busulfan , Oligospermia , Testis , Triterpenes , Ursolic Acid , Animals , Male , Triterpenes/pharmacology , Triterpenes/therapeutic use , Oligospermia/chemically induced , Oligospermia/drug therapy , Mice , Testis/drug effects , Testis/pathology , Testis/metabolism , Disease Models, Animal , Sperm Motility/drug effects , Spermatozoa/drug effects , Spermatozoa/pathology , Spermatozoa/metabolism , Reactive Oxygen Species/metabolism , Testosterone/blood , Follicle Stimulating Hormone/blood , Luteinizing Hormone/blood , Luteinizing Hormone/metabolism , Epididymis/drug effects , Epididymis/pathology , Epididymis/metabolism
15.
Oncol Res ; 32(7): 1231-1237, 2024.
Article in English | MEDLINE | ID: mdl-38948023

ABSTRACT

Background: Despite the availability of chemotherapy drugs such as 5-fluorouracil (5-FU), the treatment of some cancers such as gastric cancer remains challenging due to drug resistance and side effects. This study aimed to investigate the effect of celastrol in combination with the chemotherapy drug 5-FU on proliferation and induction of apoptosis in human gastric cancer cell lines (AGS and EPG85-257). Materials and Methods: In this in vitro study, AGS and EPG85-257 cells were treated with different concentrations of celastrol, 5-FU, and their combination. Cell proliferation was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. The synergistic effect of 5-FU and celastrol was studied using Compusyn software. The DNA content at different phases of the cell cycle and apoptosis rate was measured using flow cytometry. Results: Co-treatment with low concentrations (10% inhibitory concentration (IC10)) of celastrol and 5-FU significantly reduced IC50 (p < 0.05) so that 48 h after treatment, IC50 was calculated at 3.77 and 6.9 µM for celastrol, 20.7 and 11.6 µM for 5-FU, and 5.03 and 4.57 µM for their combination for AGS and EPG85-257 cells, respectively. The mean percentage of apoptosis for AGS cells treated with celastrol, 5-FU, and their combination was obtained 23.9, 41.2, and 61.9, and for EPG85-257 cells 5.65, 46.9, and 55.7, respectively. In addition, the 5-FU and celastrol-5-FU combination induced cell cycle arrest in the synthesis phase. Conclusions: Although celastrol could decrease the concentration of 5-fluorouracil that sufficed to suppress gastric cancer cells, additional studies are required to arrive at conclusive evidence on the anticancer effects of celastrol.


Subject(s)
Apoptosis , Cell Proliferation , Drug Synergism , Fluorouracil , Pentacyclic Triterpenes , Stomach Neoplasms , Triterpenes , Humans , Pentacyclic Triterpenes/pharmacology , Fluorouracil/pharmacology , Stomach Neoplasms/drug therapy , Stomach Neoplasms/pathology , Stomach Neoplasms/metabolism , Apoptosis/drug effects , Cell Proliferation/drug effects , Cell Line, Tumor , Triterpenes/pharmacology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Cell Cycle/drug effects
16.
AAPS PharmSciTech ; 25(6): 151, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38954171

ABSTRACT

The intranasal route has demonstrated superior systemic bioavailability due to its extensive surface area, the porous nature of the endothelial membrane, substantial blood flow, and circumvention of first-pass metabolism. In traditional medicinal practices, Bacopa monnieri, also known as Brahmi, is known for its benefits in enhancing cognitive functions and potential effects in epilepsy. This study aimed to develop and optimize a thermosensitive in-situ nasal gel for delivering Bacoside A, the principal active compound extracted from Bacopa monnieri. The formulation incorporated Poloxamer 407 as a thermogelling agent and HPMC K4M as the Mucoadhesive polymer. A 32-factorial design approach was employed for Optimization. Among the formulations. F7 exhibited the most efficient Ex-vivo permeation through the nasal mucosa, achieving 94.69 ± 2.54% permeation, and underwent a sol-gel transition at approximately 30.48 °C. The study's factorial design revealed that gelling temperature and mucoadhesive strength were critical factors influencing performance. The potential of in-situ nasal Gel (Optimized Batch-F7) for the treatment of epilepsy was demonstrated in an in-vivo investigation using a PTZ-induced convulsion model. This formulation decreased both the occurrence and intensity of seizures. The optimized formulation F7 showcases significant promise as an effective nasal delivery system for Bacoside A, offering enhanced bioavailability and potentially increased efficacy in epilepsy treatment.


Subject(s)
Administration, Intranasal , Epilepsy , Gels , Nasal Mucosa , Triterpenes , Animals , Administration, Intranasal/methods , Epilepsy/drug therapy , Gels/chemistry , Nasal Mucosa/metabolism , Nasal Mucosa/drug effects , Male , Triterpenes/administration & dosage , Triterpenes/pharmacokinetics , Triterpenes/pharmacology , Triterpenes/chemistry , Temperature , Saponins/administration & dosage , Saponins/chemistry , Saponins/pharmacology , Saponins/pharmacokinetics , Chemistry, Pharmaceutical/methods , Biological Availability , Rats , Poloxamer/chemistry , Anticonvulsants/administration & dosage , Anticonvulsants/pharmacokinetics , Anticonvulsants/pharmacology , Anticonvulsants/chemistry
17.
Toxicol In Vitro ; 99: 105867, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38848824

ABSTRACT

Pristimerin (Pris), a bioactive triterpenoid compound extracted from the Celastraceae and Hippocrateaceae families, has been reported to exhibit an anti-cancer property on various cancers. However, the effects of Pris on esophageal cancer are poorly investigated. This current study sought to explore the activity and underlying mechanism of Pris against human esophageal squamous cell carcinoma (ESCC) cells. We demonstrated that Pris showed cytotoxicity in TE-1 and TE-10 ESCC cell lines, and significantly inhibited cell viability in a concentration dependent manner. Pris induced G0/G1 phase arrest and triggered apoptosis. It was also observed that the intracellular ROS level was remarkedly increased by Pris treatment. Besides, the function of Pris mediating the activation of ER stress and the inhibition of AKT/GSK3ß signaling pathway in TE-1 and TE-10 cells was further confirmed, which resulted in cell growth inhibition. And moreover, we revealed that all of the above pathways were regulated through ROS generation. In conclusion, our findings suggested that Pris might be considered as a novel natural compound for the developing anti-cancer drug candidate for human esophageal cancer.


Subject(s)
Antineoplastic Agents , Apoptosis , Cell Survival , Endoplasmic Reticulum Stress , Esophageal Neoplasms , Glycogen Synthase Kinase 3 beta , Pentacyclic Triterpenes , Proto-Oncogene Proteins c-akt , Reactive Oxygen Species , Triterpenes , Humans , Reactive Oxygen Species/metabolism , Pentacyclic Triterpenes/pharmacology , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/metabolism , Cell Line, Tumor , Proto-Oncogene Proteins c-akt/metabolism , Glycogen Synthase Kinase 3 beta/metabolism , Endoplasmic Reticulum Stress/drug effects , Triterpenes/pharmacology , Apoptosis/drug effects , Antineoplastic Agents/pharmacology , Cell Survival/drug effects , Signal Transduction/drug effects , Cell Proliferation/drug effects , Esophageal Squamous Cell Carcinoma/drug therapy , Esophageal Squamous Cell Carcinoma/metabolism
18.
Anim Sci J ; 95(1): e13964, 2024.
Article in English | MEDLINE | ID: mdl-38831612

ABSTRACT

This study evaluated the effects of supplementation with Antrodia cinnamomea mycelium by-product (ACBP) on growth performance and immune response in weaning piglets. Total available content and antioxidant capacity of ACBP were determined. Ninety-six black pigs were randomly distributed to 24 pens. Study compared four groups which were supplemented with ACBP at 0%, 2.5%, 5%, or 10% for 6 weeks after weaning at 4 weeks. Results showed that ACBP on total phenolic, total flavonoid, and total triterpenoids contents were 13.68 mg GAE/g DW, 1.67 µg QE/g DW, and 15.6 mg/g, respectively. Weaning piglets fed 2.5% ACBP showed a significant decreased body weight gain compared with those supplemented with 5% ACBP, 10% ACBP, and control groups. Results showed that all ACBP groups increased the villi height of jejunum significantly. Incidence of diarrhea in 11 weeks with supplementation with 5% and 10% ACBP diets were lower than in control group. The 10% ACBP group showed significantly lower expression of immune response genes (IL-1ß, IL-6, IL-8, TNF-α, and IFN-γ) than the 2.5% and 5% ACBP groups. Based on results, dietary supplementation with 10% ACBP did not significantly affect body weight but could decrease piglet diarrhea condition and expression of IL-1ß and IL-6 genes.


Subject(s)
Animal Feed , Antioxidants , Diet , Dietary Supplements , Mycelium , Weaning , Weight Gain , Animals , Swine/growth & development , Swine/immunology , Weight Gain/drug effects , Diet/veterinary , Antioxidants/metabolism , Diarrhea/veterinary , Triterpenes/pharmacology , Triterpenes/administration & dosage , Gene Expression/drug effects , Cytokines/metabolism , Jejunum/metabolism , Phenols/analysis , Animal Nutritional Physiological Phenomena , Swine Diseases/microbiology , Swine Diseases/prevention & control , Swine Diseases/immunology , Polyporales/chemistry
19.
Nanotechnology ; 35(33)2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38829163

ABSTRACT

Dry eye disease (DED) is a major global eye disease leading to severe eye discomfort and even vision impairment. The incidence of DED has been gradually increasing with the high frequency of use of electronic devices. It has been demonstrated that celastrol (Cel) has excellent therapeutic efficacy in ocular disorders. However, the poor water solubility and short half-life of Cel limit its further therapeutic applications. In this work, a reactive oxygen species (ROS) sensitive polymeric micelle was fabricated for Cel delivery. The micelles improve the solubility of Cel, and the resulting Cel loaded micelles exhibit an enhanced intervention effect for DED. Thein vitroresults demonstrated that Cel-nanomedicine had a marked ROS responsive release behavior. The results ofin vitroandin vivoexperiments demonstrated that Cel has excellent biological activities to alleviate inflammation in DED by inhibiting TLR4 signaling activation and reducing pro-inflammatory cytokine expression. Therefore, the Cel nanomedicine can effectively eliminate ocular inflammation, promote corneal epithelial repair, and restore the number of goblet cells and tear secretion, providing a new option for the treatment of DED.


Subject(s)
Dry Eye Syndromes , Micelles , Nanomedicine , Pentacyclic Triterpenes , Reactive Oxygen Species , Triterpenes , Dry Eye Syndromes/drug therapy , Pentacyclic Triterpenes/pharmacology , Animals , Reactive Oxygen Species/metabolism , Mice , Nanomedicine/methods , Triterpenes/pharmacology , Triterpenes/chemistry , Inflammation/drug therapy , Toll-Like Receptor 4/metabolism , Humans , Tears/metabolism , Tears/drug effects
20.
BMC Cancer ; 24(1): 682, 2024 Jun 04.
Article in English | MEDLINE | ID: mdl-38835015

ABSTRACT

BACKGROUND: Astragaloside IV (AS-IV) is one of the basic components of Astragali radix, that has been shown to have preventive effects against various diseases, including cancers. This study aimed to explore the role of AS-IV in hepatocellular carcinoma (HCC) and its underlying mechanism. METHODS: The cell viability, glucose consumption, lactate production, and extracellular acidification rate (ECAR) in SNU-182 and Huh7 cell lines were detected by specific commercial kits. Western blot was performed to analyze the succinylation level in SNU-182 and Huh7 cell lines. The interaction between lysine acetyltransferase (KAT) 2 A and phosphoglycerate mutase 1 (PGAM1) was evaluated by co-immunoprecipitation and immunofluorescence assays. The role of KAT2A in vivo was explored using a xenografted tumor model. RESULTS: The results indicated that AS-IV treatment downregulated the protein levels of succinylation and KAT2A in SNU-182 and Huh7 cell lines. The cell viability, glucose consumption, lactate production, ECAR, and succinylation levels were decreased in AS-IV-treated SNU-182 and Huh7 cell lines, and the results were reversed after KAT2A overexpression. KAT2A interacted with PGAM1 to promote the succinylation of PGAM1 at K161 site. KAT2A overexpression promoted the viability and glycolysis of SNU-182 and Huh7 cell lines, which were partly blocked following PGAM1 inhibition. In tumor-bearing mice, AS-IV suppressed tumor growth though inhibiting KAT2A-mediated succinylation of PGAM1. CONCLUSION: AS-IV inhibited cell viability and glycolysis in HCC by regulating KAT2A-mediated succinylation of PGAM1, suggesting that AS-IV might be a potential and suitable therapeutic agent for treating HCC.


Subject(s)
Carcinoma, Hepatocellular , Cell Survival , Glycolysis , Liver Neoplasms , Phosphoglycerate Mutase , Saponins , Triterpenes , Xenograft Model Antitumor Assays , Humans , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/pathology , Liver Neoplasms/metabolism , Liver Neoplasms/drug therapy , Liver Neoplasms/pathology , Animals , Phosphoglycerate Mutase/metabolism , Mice , Glycolysis/drug effects , Triterpenes/pharmacology , Cell Survival/drug effects , Saponins/pharmacology , Cell Line, Tumor , Histone Acetyltransferases/metabolism , Mice, Nude , Cell Proliferation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL